ADMA Biologics, Inc. Announces Closing of Initial Public Offering

RAMSEY, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the closing of its previously announced initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share. Aggregate net proceeds to ADMA, after deducting underwriting discounts and commissions will be approximately $26.5 million.

Help employers find you! Check out all the jobs and post your resume.